Omacor

ApprovedSmall molecule

AstraZeneca

Omacor is one of 235 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

234

Competitors

Pipeline

Status by Indication[3][1]

Indication

Coronary Artery DiseaseActive, not recruiting

Non-Alcoholic Fatty Liver DiseaseActive, not recruiting

Alcoholic Fatty Liver DiseaseActive, not recruiting

Type 2 Diabetes MellitusActive, not recruiting

Borderline Personality DisorderActive, not recruiting

Peripheral Arterial DiseaseActive, not recruiting

Type 2 DiabetesApproved

Coronary Artery DiseasePreclinical

Active, not recruiting

Non-Alcoholic Fatty Liver DiseasePhase 3

Active, not recruiting

Alcoholic Fatty Liver DiseaseApproved

Active, not recruiting

Type 2 Diabetes MellitusApproved

Active, not recruiting

Borderline Personality DisorderApproved

Active, not recruiting

Peripheral Arterial DiseasePhase 3

Active, not recruiting

Type 2 DiabetesApproved

Approved

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Omacor

AstraZeneca

Approved

1 2

Byetta

AstraZeneca

Preclinical

55 3

Jardiance

Boehringer Ingelheim

Preclinical

31 4

NOVOLIN R

Novo Nordisk

Preclinical

5 5

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 6

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

1 7

Forxiga

AstraZeneca

Preclinical

3 8

Lovaza

AstraZeneca

Preclinical

1 9

Sulfonylureas

Eli Lilly

Preclinical

1 10

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Renal Transplantation1 trial

The Long-term Effect of Marine Omega-3 Fatty Acid Supplementation in Renal Transplantation

Completed·JJoe Chan·Phase 3·NCT03018041·174 enrolled

Borderline personality disorder1 trial

Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder

Unknown status·HHospital Universitari Vall d'Hebron Research Institute·Phase 4·NCT00437099·102 enrolled

Efficacy and Safety1 trial

An Efficacy and Safety Study of Omacor® in Taiwanese Hypertriglyceridemic Patients

Completed·EExcelsior·Phase 3·NCT01725646·253 enrolled

Alcoholic Fatty Liver Disease1 trial

Treatment of Non Alcoholic Fatty Liver Disease With n-3 Fatty Acids

Completed·UUniversity Hospital Southampton NHS Foundation Trust·Phase 4·NCT00760513·103 enrolled

Peripheral Arterial Disease1 trial

OMEGA-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Peripheral Arterial Disease

Completed·MMedical University of Vienna·Phase 3·NCT01367145·71 enrolled

8 more indications

Non-Alcoholic Fatty Liver Disease1 trial

The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease

Completed·UUniversity of Edinburgh·Phase 3·NCT01277237·50 enrolled

Type 2 Diabetes Mellitus1 trial

Omacor for the Treatment of Vascular Dysfunction in Patients With Type 2 Diabetes Mellitus

Completed·RRuhr University of Bochum·Phase 4·NCT00328536·34 enrolled

Atorvastatin1 trial

Phase I Drug-drug Interaction of Omega-3 and Atorvastatin

Unknown status·DDongKoo Bio & Pharma·Phase 1·NCT03438955·48 enrolled

HIV1 trial

Effect of Omacor on Triglycerides in HIV Infected Subjects

Terminated·SSolvay Pharmaceuticals·Phase 4·NCT00598910·51 enrolled

Prospective1 trial

A Prospective Observational Program Using Digital Technology Tools to Enhance Patient Adherence to Omacor Therapy

Completed·AAbbott··NCT03415152·3,000 enrolled

Type 2 Diabetes1 trial

A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT02370537·490 enrolled

Depression1 trial

Omacor for Perimenopausal Depression

Withdrawn·UUniversity of Arizona·Phase 2·NCT00517972

Coronary Artery Disease1 trial

The Effect of Fish Oil Supplementation on Endothelial Function, Heart Rate Variability and Intimal Media Thickness of Patients With Coronary Artery Disease

Completed·OOlive View-UCLA Education & Research Institute·N/A·NCT00454493·71 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Omacor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Omacor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Omacor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AstraZeneca

Omacor

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Renal Transplantation1 trial

Borderline personality disorder1 trial

Efficacy and Safety1 trial

Alcoholic Fatty Liver Disease1 trial

Peripheral Arterial Disease1 trial

Non-Alcoholic Fatty Liver Disease1 trial

Type 2 Diabetes Mellitus1 trial

Atorvastatin1 trial

HIV1 trial

Prospective1 trial

Type 2 Diabetes1 trial

Depression1 trial

Coronary Artery Disease1 trial

References

Drug Info

Quick Facts

Related News